Responsible DepartmentResearch PartnerResponsible DepartmentResearch PartnerThe Center of Medical Innovation and Translational ResearchThe Center of Medical Innovation and Translational ResearchImmunity and Regeneration Integration Unit30307F8F07140811Cancer immunotherapy, represented by immune checkpoint inhibitors and CAR-T cells, has dramatically improved the long-term outcome of cancer treatment. On the other hand, only a small fraction of patients benefits from their clinical efficacy, and the development of combined immunotherapy and drug modification that can exert stronger and longer therapeutic effects is urgently needed. This joint research team is working with Otsuka Pharmaceutical to develop a new treatment using what has been elucidated in basic research using preclinical murine models and in analysis using clinical specimens treated with immunotherapies. From the research on immunoregulation technology, we developed a new method for controlling the quality of immune cells by modification of glycosylation. Since this immuno-cell quality control technology can be applied for cancer immunotherapy, we are developing this technology to cell therapy in particular. Specifically, we will develop a novel cancer immunotherapy using activated T cells with newly established glycosylation modification. Furthermore, we will investigate the effector function and therapeutic duration by the induction of chemokines and neural guidance factors to regulate T-cell infiltration and maintain T-cell proliferation.The goal of our project is to develop a gene therapy targeting stem cells as a curative treatment for inherited diseases based on the collaborative research of “regeneration-inducing medicine” with StemRIM. We aim to provide non-invasive and effective gene therapy through the ex vivo approach, in which stem cells are genetically modified outside the body and then transplanted back again to the patients who have been suffering from intractable inherited diseases, such as epidermolysis bullosa, hemophilia, metabolic disorders, etc.A-2A-19Department of Respiratory Medicine and Clinical ImmunologyDepartment of Stem Cell Gene Therapy ScienceYOSHITO TakedaAssociate ProfessorKIKUCHI YasushiSpecially Appointed Associate ProfessorDepartment of Immunology and Molecular MedicineOtsuka Pharmaceutical Co., Ltd.Department of Stem Cell Gene Therapy ScienceStemRIM Inc.Development of immunomodulation technology and quality control technology in cell therapyDevelopment of stem cell-based gene therapy adapted for the regeneration-inducing medicine
元のページ ../index.html#31